Table 3.
A Summary of Clinical Studies of Leukapheresis in Patients with Hyperleukocytic Leukemia
| Author and Year | Patients | Leukoreduction Rate | Study Summary | P value |
|---|---|---|---|---|
| Porcu et al (1997)49 | 48 | > 50% | Leukapheresis could not improve one-week mortality in patients with hyperleukocytic leukemia, especially these presented with renal, neurological and respiratory complications. | >0.200 |
| Thiebaut et al (2000)50 | 53 | Median was 50% (range 0 to 91) | Patients with hyperleukocytic leukemia may benefit from initial leukapheresis. | NA |
| Giles et al (2001)51 | 71 | Median was nearly 57% (66.4/116.5) | Leukapheresis could reduce two-week mortality and achieved a higher complete remission rate compared to control group. | 0.060 |
| Chang et al (2007)52 | 22 | Not shown | Leukapheresis could not improve early mortality, on the contrary, may be detrimental. | 0.367 |
| Bug et al (2007)56 | 25 | Median was 47% | Leukapheresis could reduce the risk of early death by Day-21, but had no impact on overall survival. | 0.015 |
| Oberoi et al (2014)8 | 1354 | Not shown | Leukapheresis did not reduce early mortality in patients with hyperleukocytic leukemia. | 0.670 |
| Wong et al (2015)55 | 31 | Median was nearly 69% | Leukapheresis could not improve 30-day mortality and overall survival. | 0.250 |
| Nan et al (2017)54 | 26 | Median was 55% (range19 to 94) | Leukapheresis was associated with significantly lower 28-day mortality rate compared to control group. | 0.022 |
| Choi et al (2018)53 | 59 | Median was nearly 59% (119/202) | There was not enough evidence to show that leukapheresis had a positive effect on survival outcome and incidence of early complications. | AML: 0.846 ALL: 0.822 |
| Stahl et al (2020)58 | 113 | Not shown | Leukapheresis had no impact on 30-day mortality, achievement of complete remission, or overall survival. | 0.329 |
Abbreviation: NA, not available.